JP2015524843A5 - - Google Patents

Download PDF

Info

Publication number
JP2015524843A5
JP2015524843A5 JP2015527538A JP2015527538A JP2015524843A5 JP 2015524843 A5 JP2015524843 A5 JP 2015524843A5 JP 2015527538 A JP2015527538 A JP 2015527538A JP 2015527538 A JP2015527538 A JP 2015527538A JP 2015524843 A5 JP2015524843 A5 JP 2015524843A5
Authority
JP
Japan
Prior art keywords
compound according
piperidin
alkyl
amine
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015527538A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015524843A (ja
JP6193374B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/054715 external-priority patent/WO2014028479A1/en
Publication of JP2015524843A publication Critical patent/JP2015524843A/ja
Publication of JP2015524843A5 publication Critical patent/JP2015524843A5/ja
Application granted granted Critical
Publication of JP6193374B2 publication Critical patent/JP6193374B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015527538A 2012-08-13 2013-08-13 Gpr6モジュレーターとしてのキノキサリン誘導体 Active JP6193374B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261682704P 2012-08-13 2012-08-13
US61/682,704 2012-08-13
US201261696748P 2012-09-04 2012-09-04
US61/696,748 2012-09-04
PCT/US2013/054715 WO2014028479A1 (en) 2012-08-13 2013-08-13 Quinoxaline derivatives as gpr6 modulators

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017154601A Division JP6389933B2 (ja) 2012-08-13 2017-08-09 Gpr6モジュレーターとしてのキノキサリン誘導体

Publications (3)

Publication Number Publication Date
JP2015524843A JP2015524843A (ja) 2015-08-27
JP2015524843A5 true JP2015524843A5 (enExample) 2016-09-29
JP6193374B2 JP6193374B2 (ja) 2017-09-06

Family

ID=48998764

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2015527538A Active JP6193374B2 (ja) 2012-08-13 2013-08-13 Gpr6モジュレーターとしてのキノキサリン誘導体
JP2017154601A Active JP6389933B2 (ja) 2012-08-13 2017-08-09 Gpr6モジュレーターとしてのキノキサリン誘導体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2017154601A Active JP6389933B2 (ja) 2012-08-13 2017-08-09 Gpr6モジュレーターとしてのキノキサリン誘導体

Country Status (4)

Country Link
US (2) US9487526B2 (enExample)
EP (1) EP2882722B1 (enExample)
JP (2) JP6193374B2 (enExample)
WO (1) WO2014028479A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9487526B2 (en) * 2012-08-13 2016-11-08 Takeda Pharmaceutical Company Limited Quinoxaline derivatives as GPR6 modulators
JO3466B1 (ar) * 2013-12-20 2020-07-05 Takeda Pharmaceuticals Co مواد ضابطة لتترا هيدرو بيريدوبيرازينات من gpr6
MA39337B1 (fr) * 2014-02-14 2019-11-29 Takeda Pharmaceuticals Co Modulateurs de pyrazines de gpr6
US10179783B2 (en) 2014-02-14 2019-01-15 Taketa Pharmaceutical Company Limited Tetrahydropyridopyrazines as modulators of GPR6
FI3600312T3 (fi) * 2017-03-26 2023-07-25 Takeda Pharmaceuticals Co Piperidinyyli- ja piperatsinyylisubstituoituja heteroaromaattisia karboksamideja gpr6:n modulaattoreina
WO2024036288A2 (en) * 2022-08-11 2024-02-15 Maplight Therapeutics, Inc. Gpr6 inverse agonists
CN115636797A (zh) * 2022-10-19 2023-01-24 台州国赐医药技术有限公司 一种制备5,6-二氯-2,3-吡嗪二酸的方法
WO2025160132A1 (en) * 2024-01-23 2025-07-31 Maplight Therapeutics, Inc. Gpr6 inverse agonists

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4107288A (en) 1974-09-18 1978-08-15 Pharmaceutical Society Of Victoria Injectable compositions, nanoparticles useful therein, and process of manufacturing same
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US20070054916A1 (en) 2004-10-01 2007-03-08 Amgen Inc. Aryl nitrogen-containing bicyclic compounds and methods of use
EP1917252B1 (en) 2005-08-26 2014-01-01 Merck Serono SA Pyrazine derivatives and use as pi3k inhibitors
CA2651072A1 (en) 2006-05-01 2007-11-08 Pfizer Products Inc. Substituted 2-amino-fused heterocyclic compounds
NZ580009A (en) 2007-04-11 2012-06-29 Exelixis Inc Combination therapies comprising quinoxaline inhibitors of pi3k-alpha for use in the treatment of cancer
GB0710844D0 (en) 2007-06-06 2007-07-18 Lectus Therapeutics Ltd Potassium ion channel modulators & uses thereof
JP2010535804A (ja) * 2007-08-09 2010-11-25 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー Pi3キナーゼ阻害薬としてのキノキサリン誘導体
EP2440546B1 (en) 2009-06-12 2022-12-28 Abivax Compounds useful for treating premature aging and in particular progeria
WO2011143495A1 (en) * 2010-05-13 2011-11-17 Amgen Inc. Heteroaryloxyheterocyclyl compounds as pde10 inhibitors
EP3318561B1 (en) 2010-05-26 2021-12-22 Sunovion Pharmaceuticals Inc. Heteroaryl compounds and methods of use thereof
WO2012167423A1 (en) 2011-06-08 2012-12-13 Hutchison Medipharma Limited Substituted pyridopyrazines as novel syk inhibitors
US20150133713A1 (en) 2012-05-09 2015-05-14 Ion Beam Applications S.A. Method For Compensating The Deviation Of A Hadron Beam Produced By A Hadron-Therapy Installation
US9951088B2 (en) 2012-05-09 2018-04-24 Sunovion Pharmaceuticals Inc. D2 receptor modulators and methods of use thereof in the treatment of diseases and disorders
US9487526B2 (en) * 2012-08-13 2016-11-08 Takeda Pharmaceutical Company Limited Quinoxaline derivatives as GPR6 modulators
JO3466B1 (ar) 2013-12-20 2020-07-05 Takeda Pharmaceuticals Co مواد ضابطة لتترا هيدرو بيريدوبيرازينات من gpr6

Similar Documents

Publication Publication Date Title
JP2015524843A5 (enExample)
JP2016525075A5 (enExample)
JP2014526549A5 (enExample)
JP2013532727A5 (enExample)
NZ622769A (en) Benzothiazol-6-yl acetic acid derivatives and their use for treating an hiv infection
JP2017533968A5 (enExample)
JP2016525076A5 (enExample)
JP2014507464A5 (enExample)
JP2012501312A5 (enExample)
JP2011519854A5 (enExample)
JP2013528204A5 (enExample)
JP2013537203A5 (enExample)
JP2013530176A5 (enExample)
JP2014513110A5 (enExample)
JP2015535277A5 (enExample)
JP2013510125A5 (enExample)
JP2017502940A5 (enExample)
JP2016512834A5 (enExample)
AR081072A1 (es) Derivados de 3,3-dimetil-tetrahidroquinolina, composiciones farmaceuticas que los contienen, metodo para prepararlos y uso de los mismos para el tratamiento de la diabetes, obesidad y dislipemia
JP2011513305A5 (enExample)
JP2013505969A5 (enExample)
JP2019081762A5 (enExample)
MY148375A (en) Delta and epsilon crystal forms of imatinib mesylate
JP2020510693A5 (enExample)
JP2016501250A5 (enExample)